IASLC 浸润性肺腺癌新分级系统验证及与常见驱动突变的关系
该研究回顾性分析 950 例中国 I-III 期浸润性肺腺癌患者,验证 IASLC 病理委员会提出的新分级系统的预后分层价值,并探讨其与驱动突变及辅助化疗的关系。新分级系统较传统优势亚型分组显示出更好的生存区分度,且与 EGFR、KRAS、ALK 突变相关,高分级患者可能从辅助化疗中获益。
要点
- 新分级系统对无复发生存和总生存的区分度优于传统优势亚型分组。
- EGFR 突变多见于中级别,KRAS 突变和 ALK 融合多见于差级别。
- I b-III 期新分级高级别患者接受辅助化疗后预后改善。
核心结论
- IASLC 新分级系统是实用且高效的患者预后区分工具,应纳入病理-遗传整合亚型以改善生存预测。
- 新分级系统可能支持对侵袭性辅助化疗的患者分层。
研究设计与样本
- 回顾性分析 2008 至 2016 年 950 例中国 I-III 期浸润性肺腺癌患者,按 IASLC 拟议分级系统进行组织学模式分类。
- 将肿瘤分级与遗传数据、辅助化疗及患者结局进行相关性分析。
主要发现
- 新分级系统较传统优势亚型分组显示更好的生存区分度,无复发生存 AUC 为 0.768,总生存 AUC 为 0.775。
- 纳入淋巴血管侵犯状态后 AUC 未进一步提高。
- EGFR 突变与中级别相关(p < 0.001),KRAS 突变(p = 0.041)和 ALK 融合(p = 0.021)在差级别中显著更常见。
- 基于 EGFR 突变状态重新分类分级系统显示出极好的生存区分度(p < 0.001)。
- I b 至 III 期新分级高级别肺腺癌患者接受辅助化疗后预后改善。
临床怎么用
- 病理报告可采用 IASLC 新分级系统对浸润性肺腺癌进行分级,以辅助预后判断。
- 对 I b-III 期新分级高级别患者,可考虑辅助化疗获益。
- 整合 EGFR、KRAS、ALK 等驱动突变信息可能进一步优化风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to validate the use of the novel grading system proposed by the International Association for the Study of Lung Cancer pathology committee for prognosis stratification of invasive pulmonary adenocarcinomas (ADCs) in Chinese patients. Correlations between the grading system, common driver mutations, and adjuvant chemotherapy (ACT) were also investigated. METHODS: From 2008 to 2016, the histologic patterns of a large cohort of 950 patients with invasive ADCs (stage I-III) were retrospectively analyzed and classified according to the proposed grading system. Subsequently, tumor grading was correlated with genetic data, ACT, and patient outcome. RESULTS: Compared with conventional predominant pattern-based groups, the novel grading system carried improved survival discrimination (area under the curve = 0.768 for recurrence-free survival and 0.775 for overall survival). The area under the curve was not further improved when incorporated lymphovascular invasion status. EGFR mutations (p < 0.001) were correlated with moderate grade, whereas KRAS mutations (p = 0.041) and ALK fusions (p = 0.021) were significantly more prevalent in poor grade. The reclassification of the grading system based on EGFR mutation status revealed excellent survival discrimination (p < 0.001). In particular, patients on stage Ib to III with novel high-grade ADCs had an improved prognosis with ACT. CONCLUSIONS: The novel International Association for the Study of Lung Cancer grading system is a practical and efficient discriminator for patient prognosis and should be part of an integrated pathologic-genetic subtyping to improve survival prediction. In addition, it may support patient stratification for aggressive adjuvant chemotherapy.
引用
- Deng C, Zheng Q, Zhang Y, et al. Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations. J Thorac Oncol. 2021. PMID: 34302987. doi:10.1016/j.jtho.2021.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。